FDA sends Bausch & Lomb warning letter; Lonza picked to manufacture stems cells;

> Bausch & Lomb has received a warning letter from the FDA saying that 6 dilutions of pilocarpine hydrochloride ophthalmic solutions should be treated as prescription drugs. Letter

> The European Medicines Agency (EMA) has issued new guidance to drug manufacturers of slow release oral and patch products on what it expects them to do to show that "the prolonged release product maintains its drug release characteristics regardless of relevant variability in physiological conditions." Story

> Lonza has received a $9.5 million grant from the National Institutes of Health to provide GMP manufacturing of induced pluripotent stem cells (iPSCs) and clinical-grade iPSC-derived cell types. Item

> Hungarian drug developer Genetic Immunity has gotten approval from regulators there for a manufacturing facility in Budapest for clinical trials material and eventually for commercial production. Release

And Finally... A joint event between CPhI and a Russian pharma group will be held in April in St. Petersburg, Russia. Item

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.